Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children

For infants exposed in utero to anti-tumour necrosis factor-α [TNF] medications, it is advised that live-attenuated vaccinations be postponed until the drug is cleared, but little is known about time to clearance. To minimize delays before live-attenuated vaccination can be given, we aimed to develo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Crohn's and colitis 2022-12, Vol.16 (12), p.1835-1844
Hauptverfasser: Liu, Zheng, Julsgaard, Mette, Zhu, Xiao, Martin, Jennifer, Barclay, Murray L, Cranswick, Noel, Gibson, Peter R, Gearry, Richard B, van der Giessen, Janine, Connor, Susan J, Rosella, Ourania, Grosen, Anne, Toong, Catherine, Flanagan, Emma, Wieringa, Jantien W, Janneke van der Woude, C, Bell, Sally J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1844
container_issue 12
container_start_page 1835
container_title Journal of Crohn's and colitis
container_volume 16
creator Liu, Zheng
Julsgaard, Mette
Zhu, Xiao
Martin, Jennifer
Barclay, Murray L
Cranswick, Noel
Gibson, Peter R
Gearry, Richard B
van der Giessen, Janine
Connor, Susan J
Rosella, Ourania
Grosen, Anne
Toong, Catherine
Flanagan, Emma
Wieringa, Jantien W
Janneke van der Woude, C
Bell, Sally J
description For infants exposed in utero to anti-tumour necrosis factor-α [TNF] medications, it is advised that live-attenuated vaccinations be postponed until the drug is cleared, but little is known about time to clearance. To minimize delays before live-attenuated vaccination can be given, we aimed to develop a pharmacokinetic model to predict time-to-clearance in infants exposed during pregnancy. We prospectively followed in utero infliximab/adalimumab-exposed infants of mothers with inflammatory bowel disease across four countries between 2011 and 2018. Infants with a detectable anti-TNF umbilical-cord level and at least one other blood sample during the first year of life were included. Overall, 107 infants were enrolled, including 166 blood samples from 71 infliximab-exposed infants and 77 samples from 36 adalimumab-exposed infants. Anti-TNF was detectable in 23% [n = 25] of infants at 6 months. At 12 months, adalimumab was not detected but 4% [n = 3] had detectable infliximab. A Bayesian forecasting method was developed using a one-compartment pharmacokinetic model. Model validation showed that the predicted clearing time was in accordance with the measured observations. A clinician-friendly online calculator was developed for calculating full anti-TNF clearing time: https://xiaozhu.shinyapps.io/antiTNFcalculator2/. Almost one-quarter of infants born to mothers receiving anti-TNF during pregnancy have detectable anti-TNF at 6 months. To limit the time to live-attenuated vaccination in infants of mothers receiving anti-TNF during pregnancy, the results of a cord drug level at birth and a second sample ≥ 1 month thereafter can be used to estimate the time for full anti-TNF clearance in these children.
doi_str_mv 10.1093/ecco-jcc/jjac093
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ecco_jcc_jjac093</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>35779236</sourcerecordid><originalsourceid>FETCH-LOGICAL-c299t-758dd50426a797c90363eea4f1c25fdf1b6593bf84e956c9d934e5e43a2398bd3</originalsourceid><addsrcrecordid>eNo9kF1PgzAUhhujcXN675XpH8AVSin1jpCpS5Zo4uYtKf1wJdASKGb7Cf5rwalX5_N9c84DwG2I7kPE8FIJ4YJKiGVVcTE2zsA8TGkSxDFl5z85DhiLkxm46vsKIcIITS_BDBNKWYSTOfjamsbYD-g03JhPBTPvlR24VxK-cyGM5d44C42Fa6u59T1cHVrXj2PvplZtDqbhJXQdzCSvTTNM1bi-86pzDzCDr53rWyX85J67ves8fPODPE5LIaIw35tadspegwvN617d_MYF2D2utvlzsHl5WufZJhARYz6gJJWSoDhKOGVUMIQTrBSPdSgioqUOy4QwXOo0VowkgkmGY0VUjHmEWVpKvADo5CvGw_pO6aLtxhe6YxGiYqJaTFSLkWrxS3WU3J0k7VA2Sv4L_jDib1bWd14</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Liu, Zheng ; Julsgaard, Mette ; Zhu, Xiao ; Martin, Jennifer ; Barclay, Murray L ; Cranswick, Noel ; Gibson, Peter R ; Gearry, Richard B ; van der Giessen, Janine ; Connor, Susan J ; Rosella, Ourania ; Grosen, Anne ; Toong, Catherine ; Flanagan, Emma ; Wieringa, Jantien W ; Janneke van der Woude, C ; Bell, Sally J</creator><creatorcontrib>Liu, Zheng ; Julsgaard, Mette ; Zhu, Xiao ; Martin, Jennifer ; Barclay, Murray L ; Cranswick, Noel ; Gibson, Peter R ; Gearry, Richard B ; van der Giessen, Janine ; Connor, Susan J ; Rosella, Ourania ; Grosen, Anne ; Toong, Catherine ; Flanagan, Emma ; Wieringa, Jantien W ; Janneke van der Woude, C ; Bell, Sally J ; CARINA Study Group ; The CARINA Study Group</creatorcontrib><description>For infants exposed in utero to anti-tumour necrosis factor-α [TNF] medications, it is advised that live-attenuated vaccinations be postponed until the drug is cleared, but little is known about time to clearance. To minimize delays before live-attenuated vaccination can be given, we aimed to develop a pharmacokinetic model to predict time-to-clearance in infants exposed during pregnancy. We prospectively followed in utero infliximab/adalimumab-exposed infants of mothers with inflammatory bowel disease across four countries between 2011 and 2018. Infants with a detectable anti-TNF umbilical-cord level and at least one other blood sample during the first year of life were included. Overall, 107 infants were enrolled, including 166 blood samples from 71 infliximab-exposed infants and 77 samples from 36 adalimumab-exposed infants. Anti-TNF was detectable in 23% [n = 25] of infants at 6 months. At 12 months, adalimumab was not detected but 4% [n = 3] had detectable infliximab. A Bayesian forecasting method was developed using a one-compartment pharmacokinetic model. Model validation showed that the predicted clearing time was in accordance with the measured observations. A clinician-friendly online calculator was developed for calculating full anti-TNF clearing time: https://xiaozhu.shinyapps.io/antiTNFcalculator2/. Almost one-quarter of infants born to mothers receiving anti-TNF during pregnancy have detectable anti-TNF at 6 months. To limit the time to live-attenuated vaccination in infants of mothers receiving anti-TNF during pregnancy, the results of a cord drug level at birth and a second sample ≥ 1 month thereafter can be used to estimate the time for full anti-TNF clearance in these children.</description><identifier>ISSN: 1873-9946</identifier><identifier>EISSN: 1876-4479</identifier><identifier>DOI: 10.1093/ecco-jcc/jjac093</identifier><identifier>PMID: 35779236</identifier><language>eng</language><publisher>England</publisher><subject>Adalimumab - therapeutic use ; Bayes Theorem ; Child ; Female ; Humans ; Infant ; Infant, Newborn ; Inflammatory Bowel Diseases - drug therapy ; Infliximab - therapeutic use ; Maternal Exposure ; Pregnancy ; Prospective Studies ; Tumor Necrosis Factor Inhibitors - therapeutic use ; Vaccination ; Vaccines, Attenuated - administration &amp; dosage</subject><ispartof>Journal of Crohn's and colitis, 2022-12, Vol.16 (12), p.1835-1844</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c299t-758dd50426a797c90363eea4f1c25fdf1b6593bf84e956c9d934e5e43a2398bd3</citedby><cites>FETCH-LOGICAL-c299t-758dd50426a797c90363eea4f1c25fdf1b6593bf84e956c9d934e5e43a2398bd3</cites><orcidid>0000-0003-3295-619X ; 0000-0002-3911-4780 ; 0000-0001-5606-0270 ; 0000-0003-3070-8950</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35779236$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Zheng</creatorcontrib><creatorcontrib>Julsgaard, Mette</creatorcontrib><creatorcontrib>Zhu, Xiao</creatorcontrib><creatorcontrib>Martin, Jennifer</creatorcontrib><creatorcontrib>Barclay, Murray L</creatorcontrib><creatorcontrib>Cranswick, Noel</creatorcontrib><creatorcontrib>Gibson, Peter R</creatorcontrib><creatorcontrib>Gearry, Richard B</creatorcontrib><creatorcontrib>van der Giessen, Janine</creatorcontrib><creatorcontrib>Connor, Susan J</creatorcontrib><creatorcontrib>Rosella, Ourania</creatorcontrib><creatorcontrib>Grosen, Anne</creatorcontrib><creatorcontrib>Toong, Catherine</creatorcontrib><creatorcontrib>Flanagan, Emma</creatorcontrib><creatorcontrib>Wieringa, Jantien W</creatorcontrib><creatorcontrib>Janneke van der Woude, C</creatorcontrib><creatorcontrib>Bell, Sally J</creatorcontrib><creatorcontrib>CARINA Study Group</creatorcontrib><creatorcontrib>The CARINA Study Group</creatorcontrib><title>Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children</title><title>Journal of Crohn's and colitis</title><addtitle>J Crohns Colitis</addtitle><description>For infants exposed in utero to anti-tumour necrosis factor-α [TNF] medications, it is advised that live-attenuated vaccinations be postponed until the drug is cleared, but little is known about time to clearance. To minimize delays before live-attenuated vaccination can be given, we aimed to develop a pharmacokinetic model to predict time-to-clearance in infants exposed during pregnancy. We prospectively followed in utero infliximab/adalimumab-exposed infants of mothers with inflammatory bowel disease across four countries between 2011 and 2018. Infants with a detectable anti-TNF umbilical-cord level and at least one other blood sample during the first year of life were included. Overall, 107 infants were enrolled, including 166 blood samples from 71 infliximab-exposed infants and 77 samples from 36 adalimumab-exposed infants. Anti-TNF was detectable in 23% [n = 25] of infants at 6 months. At 12 months, adalimumab was not detected but 4% [n = 3] had detectable infliximab. A Bayesian forecasting method was developed using a one-compartment pharmacokinetic model. Model validation showed that the predicted clearing time was in accordance with the measured observations. A clinician-friendly online calculator was developed for calculating full anti-TNF clearing time: https://xiaozhu.shinyapps.io/antiTNFcalculator2/. Almost one-quarter of infants born to mothers receiving anti-TNF during pregnancy have detectable anti-TNF at 6 months. To limit the time to live-attenuated vaccination in infants of mothers receiving anti-TNF during pregnancy, the results of a cord drug level at birth and a second sample ≥ 1 month thereafter can be used to estimate the time for full anti-TNF clearance in these children.</description><subject>Adalimumab - therapeutic use</subject><subject>Bayes Theorem</subject><subject>Child</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Inflammatory Bowel Diseases - drug therapy</subject><subject>Infliximab - therapeutic use</subject><subject>Maternal Exposure</subject><subject>Pregnancy</subject><subject>Prospective Studies</subject><subject>Tumor Necrosis Factor Inhibitors - therapeutic use</subject><subject>Vaccination</subject><subject>Vaccines, Attenuated - administration &amp; dosage</subject><issn>1873-9946</issn><issn>1876-4479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kF1PgzAUhhujcXN675XpH8AVSin1jpCpS5Zo4uYtKf1wJdASKGb7Cf5rwalX5_N9c84DwG2I7kPE8FIJ4YJKiGVVcTE2zsA8TGkSxDFl5z85DhiLkxm46vsKIcIITS_BDBNKWYSTOfjamsbYD-g03JhPBTPvlR24VxK-cyGM5d44C42Fa6u59T1cHVrXj2PvplZtDqbhJXQdzCSvTTNM1bi-86pzDzCDr53rWyX85J67ves8fPODPE5LIaIw35tadspegwvN617d_MYF2D2utvlzsHl5WufZJhARYz6gJJWSoDhKOGVUMIQTrBSPdSgioqUOy4QwXOo0VowkgkmGY0VUjHmEWVpKvADo5CvGw_pO6aLtxhe6YxGiYqJaTFSLkWrxS3WU3J0k7VA2Sv4L_jDib1bWd14</recordid><startdate>20221205</startdate><enddate>20221205</enddate><creator>Liu, Zheng</creator><creator>Julsgaard, Mette</creator><creator>Zhu, Xiao</creator><creator>Martin, Jennifer</creator><creator>Barclay, Murray L</creator><creator>Cranswick, Noel</creator><creator>Gibson, Peter R</creator><creator>Gearry, Richard B</creator><creator>van der Giessen, Janine</creator><creator>Connor, Susan J</creator><creator>Rosella, Ourania</creator><creator>Grosen, Anne</creator><creator>Toong, Catherine</creator><creator>Flanagan, Emma</creator><creator>Wieringa, Jantien W</creator><creator>Janneke van der Woude, C</creator><creator>Bell, Sally J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-3295-619X</orcidid><orcidid>https://orcid.org/0000-0002-3911-4780</orcidid><orcidid>https://orcid.org/0000-0001-5606-0270</orcidid><orcidid>https://orcid.org/0000-0003-3070-8950</orcidid></search><sort><creationdate>20221205</creationdate><title>Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children</title><author>Liu, Zheng ; Julsgaard, Mette ; Zhu, Xiao ; Martin, Jennifer ; Barclay, Murray L ; Cranswick, Noel ; Gibson, Peter R ; Gearry, Richard B ; van der Giessen, Janine ; Connor, Susan J ; Rosella, Ourania ; Grosen, Anne ; Toong, Catherine ; Flanagan, Emma ; Wieringa, Jantien W ; Janneke van der Woude, C ; Bell, Sally J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c299t-758dd50426a797c90363eea4f1c25fdf1b6593bf84e956c9d934e5e43a2398bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adalimumab - therapeutic use</topic><topic>Bayes Theorem</topic><topic>Child</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Inflammatory Bowel Diseases - drug therapy</topic><topic>Infliximab - therapeutic use</topic><topic>Maternal Exposure</topic><topic>Pregnancy</topic><topic>Prospective Studies</topic><topic>Tumor Necrosis Factor Inhibitors - therapeutic use</topic><topic>Vaccination</topic><topic>Vaccines, Attenuated - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Zheng</creatorcontrib><creatorcontrib>Julsgaard, Mette</creatorcontrib><creatorcontrib>Zhu, Xiao</creatorcontrib><creatorcontrib>Martin, Jennifer</creatorcontrib><creatorcontrib>Barclay, Murray L</creatorcontrib><creatorcontrib>Cranswick, Noel</creatorcontrib><creatorcontrib>Gibson, Peter R</creatorcontrib><creatorcontrib>Gearry, Richard B</creatorcontrib><creatorcontrib>van der Giessen, Janine</creatorcontrib><creatorcontrib>Connor, Susan J</creatorcontrib><creatorcontrib>Rosella, Ourania</creatorcontrib><creatorcontrib>Grosen, Anne</creatorcontrib><creatorcontrib>Toong, Catherine</creatorcontrib><creatorcontrib>Flanagan, Emma</creatorcontrib><creatorcontrib>Wieringa, Jantien W</creatorcontrib><creatorcontrib>Janneke van der Woude, C</creatorcontrib><creatorcontrib>Bell, Sally J</creatorcontrib><creatorcontrib>CARINA Study Group</creatorcontrib><creatorcontrib>The CARINA Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of Crohn's and colitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Zheng</au><au>Julsgaard, Mette</au><au>Zhu, Xiao</au><au>Martin, Jennifer</au><au>Barclay, Murray L</au><au>Cranswick, Noel</au><au>Gibson, Peter R</au><au>Gearry, Richard B</au><au>van der Giessen, Janine</au><au>Connor, Susan J</au><au>Rosella, Ourania</au><au>Grosen, Anne</au><au>Toong, Catherine</au><au>Flanagan, Emma</au><au>Wieringa, Jantien W</au><au>Janneke van der Woude, C</au><au>Bell, Sally J</au><aucorp>CARINA Study Group</aucorp><aucorp>The CARINA Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children</atitle><jtitle>Journal of Crohn's and colitis</jtitle><addtitle>J Crohns Colitis</addtitle><date>2022-12-05</date><risdate>2022</risdate><volume>16</volume><issue>12</issue><spage>1835</spage><epage>1844</epage><pages>1835-1844</pages><issn>1873-9946</issn><eissn>1876-4479</eissn><abstract>For infants exposed in utero to anti-tumour necrosis factor-α [TNF] medications, it is advised that live-attenuated vaccinations be postponed until the drug is cleared, but little is known about time to clearance. To minimize delays before live-attenuated vaccination can be given, we aimed to develop a pharmacokinetic model to predict time-to-clearance in infants exposed during pregnancy. We prospectively followed in utero infliximab/adalimumab-exposed infants of mothers with inflammatory bowel disease across four countries between 2011 and 2018. Infants with a detectable anti-TNF umbilical-cord level and at least one other blood sample during the first year of life were included. Overall, 107 infants were enrolled, including 166 blood samples from 71 infliximab-exposed infants and 77 samples from 36 adalimumab-exposed infants. Anti-TNF was detectable in 23% [n = 25] of infants at 6 months. At 12 months, adalimumab was not detected but 4% [n = 3] had detectable infliximab. A Bayesian forecasting method was developed using a one-compartment pharmacokinetic model. Model validation showed that the predicted clearing time was in accordance with the measured observations. A clinician-friendly online calculator was developed for calculating full anti-TNF clearing time: https://xiaozhu.shinyapps.io/antiTNFcalculator2/. Almost one-quarter of infants born to mothers receiving anti-TNF during pregnancy have detectable anti-TNF at 6 months. To limit the time to live-attenuated vaccination in infants of mothers receiving anti-TNF during pregnancy, the results of a cord drug level at birth and a second sample ≥ 1 month thereafter can be used to estimate the time for full anti-TNF clearance in these children.</abstract><cop>England</cop><pmid>35779236</pmid><doi>10.1093/ecco-jcc/jjac093</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-3295-619X</orcidid><orcidid>https://orcid.org/0000-0002-3911-4780</orcidid><orcidid>https://orcid.org/0000-0001-5606-0270</orcidid><orcidid>https://orcid.org/0000-0003-3070-8950</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1873-9946
ispartof Journal of Crohn's and colitis, 2022-12, Vol.16 (12), p.1835-1844
issn 1873-9946
1876-4479
language eng
recordid cdi_crossref_primary_10_1093_ecco_jcc_jjac093
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection
subjects Adalimumab - therapeutic use
Bayes Theorem
Child
Female
Humans
Infant
Infant, Newborn
Inflammatory Bowel Diseases - drug therapy
Infliximab - therapeutic use
Maternal Exposure
Pregnancy
Prospective Studies
Tumor Necrosis Factor Inhibitors - therapeutic use
Vaccination
Vaccines, Attenuated - administration & dosage
title Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T17%3A54%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Timing%20of%20Live%20Attenuated%20Vaccination%20in%20Infants%20Exposed%20to%20Infliximab%20or%20Adalimumab%20in%20Utero:%20A%20Prospective%20Cohort%20Study%20in%20107%20Children&rft.jtitle=Journal%20of%20Crohn's%20and%20colitis&rft.au=Liu,%20Zheng&rft.aucorp=CARINA%20Study%20Group&rft.date=2022-12-05&rft.volume=16&rft.issue=12&rft.spage=1835&rft.epage=1844&rft.pages=1835-1844&rft.issn=1873-9946&rft.eissn=1876-4479&rft_id=info:doi/10.1093/ecco-jcc/jjac093&rft_dat=%3Cpubmed_cross%3E35779236%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35779236&rfr_iscdi=true